ClinicalTrials.Veeva

Menu
F

Frontier Clinical Research, LLC | Smithfield , PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
Atogepant
Linaclotide
Orforglipron
Tolperisone
Baloxavir Marboxil
Tenapanor
Lasmiditan
Guselkumab
LY573144

Parent organization

This site is a part of Frontier Clinical Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 48 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants w...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Orforglipron

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overw...

Enrolling
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with...

Not yet enrolling
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and...

Active, not recruiting
Functional Constipation (FC)
Chronic Idiopathic Constipation (CIC)
Drug: Linaclotide
Drug: Placebo for Linaclotide

The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1...

Enrolling
Influenza
Drug: Baloxavir Marboxil

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North...

Active, not recruiting
Lyme Disease
Biological: VLA15
Other: Saline

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor 50 MG
Drug: Placebo

Trial sponsors

AbbVie logo
Allergan logo
Lilly logo
Janssen (J&J Innovative Medicine) logo
Ardelyx logo
N
Novartis logo
Roche logo
A
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems